Loading
A phase 3 trial of OH2 in melanoma, run by Binhui Biopharmaceutical Co., Ltd., now recruiting.
OH2 Injection in Melanoma is a phase 3 interventional study registered as NCT05868707 by Binhui Biopharmaceutical Co., Ltd., with 340 participants planned, started 2023-03-08 and due to reach its primary completion in 2026-03. Interventions recorded: OH2 and Salvage chemotherapy or best supportive care.
Shares Binhui Biopharmaceutical and the tag pipeline.
Shares Binhui Biopharmaceutical and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.